Lingohr Asset Management GmbH Trims Position in Thermo Fisher Scientific Inc. $TMO

Lingohr Asset Management GmbH lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 90.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 900 shares of the medical research company’s stock after selling 8,068 shares during the period. Lingohr Asset Management GmbH’s holdings in Thermo Fisher Scientific were worth $365,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Monograph Wealth Advisors LLC raised its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company’s stock valued at $4,507,000 after buying an additional 23 shares during the period. Intergy Private Wealth LLC raised its holdings in Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company’s stock valued at $208,000 after buying an additional 23 shares during the period. Root Financial Partners LLC raised its holdings in Thermo Fisher Scientific by 5.0% in the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock valued at $252,000 after buying an additional 24 shares during the period. Finally, Rossmore Private Capital raised its holdings in Thermo Fisher Scientific by 0.5% in the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after buying an additional 24 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on TMO shares. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating on the stock. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, HSBC reissued a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Seventeen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $592.24.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $479.48 on Monday. The stock has a 50 day moving average price of $466.86 and a 200 day moving average price of $450.58. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.